education of our political leaders and the 1 public." 2 DR. LANGER: That's pretty good. 3 DR. NEREM: I mean, I think what we have to talk about is not who we can give some 5 statement to --DR. LANGER: Right. 7 DR. NEREM: -- but what are we going 8 to do. 9 DR. LANGER: That's a good statement. 10 VOICES: That's a good statement. 11 DR. FENNEMA: The statement is 12 meaningless. The activity is what counts. 13 DR. LANGER: Right. So the question 14 is do we want to put a statement down or not? 15 Do we want to write a paper or not? 16 DR. DAVIS: I agree, but let's not 17 18 solve that today. DR. LANGER: I agree with that, too. 19 I think there have been a lot of good 20 suggestions, and we should find the time to 21 continue this discussion. But I think that 22 comes closest to the spirit. I agree with what 23

ago, it was well defined in there that one of

everybody is saying.

1

23

the difficulties that the Agency is facing is a 1 2 shortage of resources. So if you wanted to reference 3 something and extend it, update it to today, in 4 the context of looking at new technology, new 5 science, new issues, that's another. I will 6 7 provide you with the comments. DR. LANGER: Yes, it would probably be 8 9 good. I was actually on that committee. 10 DR. SCHWETZ: So we can send it to 11 everybody so they have it. 12 DR. LANGER: Yes. Okay. 13 DR. SCHWETZ: That can be part of your 14 thought process. 15 DR. LANGER: That's a good idea. 16 Other comments on action items? 17 Bob, you did. DR. BUCHANAN: I was just reflecting 18 19 on this process and we can help you with, I 20 believe, with Liz's agreement, I don't know if 2.1 we've made a concerted effort to get out to the 22 professional societies, to the trade

organizations, to the Trade Press, the role of

23

the Science Board, how important it is to us, convincing them that when you do speak they ought to listen.

I think that's a role that we could take on in playing up the activities of this Board so that we sort of lay the groundwork for when you do talk that somebody wants to hear you.

DR. LANGER: Yes. That's true. Okay, that's a good suggestion.

Other comments on this?
(No response.)

We're going to leave those three action items as they are.

The other topics are other discussion items, future direction? I'll be happy to hear from anybody in this room or the Science Board or members of the FDA on this. Any comments, suggestions on things we ought to go over or do or do differently?

DR. JACOBSON: Let me just ask. One of the issues was what topics, if any, did you want to go into in more depth.

1.3

2.3

2.3

I know Bob Nerem had asked actually before this meeting for a further discussion of tissue engineering, and I just wanted to ask you if you have other suggestions, other topics. You don't have to say it here today. You can just get to us as we plan for the April meeting.

Bob, I am assuming you still are interested in that?

DR. NEREM: Yes. And I'm interested in it both because of my interest in engineering, but also as an example of a technology that cuts across the Agency.

And recognizing the political constraints, one still has to wonder about if FDA is organized the way it should be for the 21st century.

DR. LANGER: Right.

DR. JACOBSON: Good question.

DR. LANGER: Other points that anybody wants to make?

(No response.)

DR. LANGER: Okay. Then the next

meeting is the 13th of April, I believe. 1 Can I get a motion to adjourn. 2 DR. ANDERS: So moved. 3 DR. NEREM: So moved. 4 I hope that's not a Friday. 5 DR. LANGER: Is that bad for you? 6 DR. NEREM: Friday the 13th. 7 DR. LANGER: Friday the 13th. Yes. 8 It will be a lucky day. 9 Thank you all very much for coming. 10 (Whereupon, at 3:35 p.m., the meeting 11 was adjourned.) 12 13 14